BI
ZVRA icon

Binnacle Investments’s Zevra Therapeutics ZVRA Stock Holding History

Binnacle Investments’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.1K Sell
431
-30
-7% -$301 ﹤0.01% 563
2025
Q2 		$4.06K Sell
461
-187
-29% -$1.52K ﹤0.01% 487
2025
Q1 		$4.85K Buy
+648
New +$5.15K ﹤0.01% 430

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Binnacle Investments's ZVRA Position: Q3 2025 in Review

Binnacle Investments reduced its Zevra Therapeutics (ZVRA) stake by 6.5% in Q3 2025, selling an estimated $301 and leaving 431 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #563.

Binnacle Investments first reported a position in ZVRA in Q1 2025 and has held it in 3 quarters since. The position peaked at $4.85K in Q1 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

  • Binnacle Investments held 431 shares of Zevra Therapeutics worth $4.1K as of Q3 2025.
  • Binnacle Investments sold 30 Zevra Therapeutics shares in Q3 2025, an estimated $301.
  • Zevra Therapeutics made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #563 holding.
  • Binnacle Investments first reported a position in Zevra Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Binnacle Investments's Zevra Therapeutics position peaked at $4.85K in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.